Johnson & Johnson said it closed its $3.05 billion acquisition of Halda Therapeutics, and that the deal is now expected to ding its adjusted earnings by 20 cents a share.
Upon disclosing the deal last month, Johnson & Johnson said it would reduce 2026 adjusted earnings by about 15 cents a share due to short-term financing and a charge related to equity awards for Halda employees.
The New Brunswick, N.J., company said Monday that since the deal closed in 2025, it anticipates a ding to adjusted earnings in the fourth quarter, as well as next year. The total hit is now expected to be about 20 cents a share, split equally between 2025 and 2026.
Johnson & Johnson said it will provide additional details during its fourth-quarter earnings call, scheduled for Jan. 21.
The Halda deal aims to bolster the healthcare company's oncology pipeline. With the buy, Johnson & Johnson adds to its portfolio Halda's lead candidate, HLD-0915, a once-daily therapy for prostate cancer.
The deal additionally adds several earlier candidates for breast, lung and multiple other tumor types.
"Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates," John Reed, executive vice president of innovative medicine and R&D, said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.